Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Texas Oncology-Plano East
mi
from
Plano, TX
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Texas Oncology-Plano East
mi
from
Plano, TX
Click here to add this to my saved trials
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Tyler Cancer Center
mi
from
Tyler, TX
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Click here to add this to my saved trials
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Virginia Oncology Associates
mi
from
Norfolk, VA
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
Click here to add this to my saved trials
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Local Institution
mi
from
Spokane, WA
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Local Institution
mi
from
Spokane, WA
Click here to add this to my saved trials
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Cancer Care Northwest
mi
from
Spokane, WA
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated:  6/18/2012
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Status: Enrolling
Updated: 6/18/2012
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
Medical Oncology Hematology, Stamford Hospital
mi
from
Stamford, CT
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
Medical Oncology Hematology, Stamford Hospital
mi
from
Stamford, CT
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients
Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients
Status: Enrolling
Updated:  6/21/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients
Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients
Status: Enrolling
Updated: 6/21/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients
Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients
Status: Enrolling
Updated:  6/21/2012
Medical University of South Carolina
mi
from
Charleston, SC
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients
Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients
Status: Enrolling
Updated: 6/21/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Promoting a Healthier Lifestyle Among Breast Cancer Survivors
Motivational Interviewing to Promote Physical Activity in Breast Cancer Survivors
Status: Archived
Updated:  6/25/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Promoting a Healthier Lifestyle Among Breast Cancer Survivors
Motivational Interviewing to Promote Physical Activity in Breast Cancer Survivors
Status: Archived
Updated: 6/25/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Status: Enrolling
Updated:  7/10/2012
Yale Cancer Center
mi
from
New Haven, CT
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Status: Enrolling
Updated: 7/10/2012
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Status: Enrolling
Updated:  7/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Status: Enrolling
Updated: 7/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  7/16/2012
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 7/16/2012
Banner MD Anderson Cancer Center
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  7/16/2012
The Methodist Hospital Cancer Center
mi
from
Houston, TX
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer
A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 7/16/2012
The Methodist Hospital Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: Enrolling
Updated:  7/18/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: Enrolling
Updated: 7/18/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: Enrolling
Updated:  7/18/2012
The West Clinic, PC
mi
from
Memphis, TN
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: Enrolling
Updated: 7/18/2012
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: Enrolling
Updated:  7/18/2012
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: Enrolling
Updated: 7/18/2012
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: Enrolling
Updated:  7/18/2012
Northwest Cancer Specialists
mi
from
Vancouver, WA
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
Status: Enrolling
Updated: 7/18/2012
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer
Status: Enrolling
Updated:  7/19/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer
Status: Enrolling
Updated: 7/19/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer
Status: Enrolling
Updated:  7/19/2012
Emory Midtown (Crawford Long Hospital)
mi
from
Atlanta, GA
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer
Status: Enrolling
Updated: 7/19/2012
Emory Midtown (Crawford Long Hospital)
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer
Status: Enrolling
Updated:  7/19/2012
Grady Memorial Hospital
mi
from
Atlanta, GA
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer
Status: Enrolling
Updated: 7/19/2012
Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pilot Study for Young Women's Intervention
Qualitative Assessment and Pilot Study for Young Women's Intervention
Status: Enrolling
Updated:  7/19/2012
Eastern Maine Medical Center
mi
from
Bangor, ME
Pilot Study for Young Women's Intervention
Qualitative Assessment and Pilot Study for Young Women's Intervention
Status: Enrolling
Updated: 7/19/2012
Eastern Maine Medical Center
mi
from
Bangor, ME
Click here to add this to my saved trials
Pilot Study for Young Women's Intervention
Qualitative Assessment and Pilot Study for Young Women's Intervention
Status: Enrolling
Updated:  7/19/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Pilot Study for Young Women's Intervention
Qualitative Assessment and Pilot Study for Young Women's Intervention
Status: Enrolling
Updated: 7/19/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Pilot Study for Young Women's Intervention
Qualitative Assessment and Pilot Study for Young Women's Intervention
Status: Enrolling
Updated:  7/19/2012
Lowell General Hospital
mi
from
Lowell, MA
Pilot Study for Young Women's Intervention
Qualitative Assessment and Pilot Study for Young Women's Intervention
Status: Enrolling
Updated: 7/19/2012
Lowell General Hospital
mi
from
Lowell, MA
Click here to add this to my saved trials
Pilot Study for Young Women's Intervention
Qualitative Assessment and Pilot Study for Young Women's Intervention
Status: Enrolling
Updated:  7/19/2012
Texas Oncology Cancer Center
mi
from
Austin, TX
Pilot Study for Young Women's Intervention
Qualitative Assessment and Pilot Study for Young Women's Intervention
Status: Enrolling
Updated: 7/19/2012
Texas Oncology Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  7/20/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 7/20/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  7/20/2012
The Moses H. Cone Regional Cancer Center
mi
from
Greensboro, NC
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 7/20/2012
The Moses H. Cone Regional Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  7/20/2012
The West Clinic, PC
mi
from
Memphis, TN
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 7/20/2012
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated:  7/20/2012
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer
Status: Enrolling
Updated: 7/20/2012
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
A Phase II Study of Combined Fulvestrant (Faslodex) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Status: Enrolling
Updated:  8/6/2012
University of Kentucky
mi
from
Lexington, KY
Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
A Phase II Study of Combined Fulvestrant (Faslodex) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Status: Enrolling
Updated: 8/6/2012
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
City of Hope National Medical Center SC-2
mi
from
Duarte, CA
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
City of Hope National Medical Center SC-2
mi
from
Duarte, CA
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
UCLA/ University of California Los Angeles UCLA LeConte Location
mi
from
Los Angeles, CA
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
UCLA/ University of California Los Angeles UCLA LeConte Location
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of California San Francisco UCSF (SC)
mi
from
San Francisco, CA
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of California San Francisco UCSF (SC)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Florida Cancer Specialists Sarasota Office
mi
from
Fort Myers, FL
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Florida Cancer Specialists Sarasota Office
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Rush University Medical Center Rush 3
mi
from
Chicago, IL
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Rush University Medical Center Rush 3
mi
from
Chicago, IL
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Washington University School Of Medicine-Siteman Cancer Ctr SC
mi
from
St. Louis, MO
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Washington University School Of Medicine-Siteman Cancer Ctr SC
mi
from
St. Louis, MO
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Montefiore Medical Center Montefiore Medical Center (SC)
mi
from
Bronx, NY
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Montefiore Medical Center Montefiore Medical Center (SC)
mi
from
Bronx, NY
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Duke University Medical Center Blue Zone Building
mi
from
Durham, NC
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Duke University Medical Center Blue Zone Building
mi
from
Durham, NC
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of Oklahoma Health Sciences Center OUHSC - SC
mi
from
Oklahoma City, OK
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of Oklahoma Health Sciences Center OUHSC - SC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of Pittsburgh University of Pittsburgh (SC)
mi
from
Pittsburgh, PA
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of Pittsburgh University of Pittsburgh (SC)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Sarah Cannon Research Institute Sarah Cannon Research (SC)
mi
from
Nashville, TN
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Sarah Cannon Research Institute Sarah Cannon Research (SC)
mi
from
Nashville, TN
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Sammons Cancer Center Sammons Cancer Center SC-2
mi
from
Dallas, TX
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Sammons Cancer Center Sammons Cancer Center SC-2
mi
from
Dallas, TX
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)
mi
from
San Antonio, TX
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Click here to add this to my saved trials